Consenso de recomendaciones para la mejora de la coordinación asistencial inter e intra-centros en el abordaje de la hemofilia / Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia

Objetivo: definir las recomendaciones consensuadas para mejorar la coordinación asistencial entre Farmacia Hospitalaria, Hematología y Enfermería, inter e intra-centros, en la atención a los pacientes con hemofilia. Método: se identificaron y valoraron las recomendaciones para la mejora de la coordinación asistencial en el abordaje de los pacientes con hemofilia, por parte de un panel multidisciplinar de profesionales con experiencia en este campo (Farmacia Hospitalaria, Hematología y Enfermería) y apoyado en la evidencia científica. La valoración de las recomendaciones identificadas se realizó por metodología de consenso Rand/UCLA (Delphi-adaptado) con base en su adecuación y, posteriormente, a su necesidad. En ambos casos, se empleó la escala ordinal de Likert. Los datos se analizaron estadísticamente a través de diferentes métricas. Resultados: se identificaron 53 recomendaciones para la mejora de la coordinación asistencial entre Farmacia Hospitalaria, Hematología y Enfermería en el manejo del paciente con hemofilia, agrupadas en 8 ámbitos de actuación: i) Unidades de Hemofilia, centros de referencia y abordaje multidisciplinar; ii) papel de Hematología, Farmacia Hospitalaria y Enfermería en el recorrido asistencial de los pacientes con hemofilia; iii) telefarmacia y telemedicina; iv) monitorización farmacocinética; v) transición al régimen de paciente adulto; vi) educación sanitaria al paciente; vii) cirugía, urgencias e ingreso hospitalario; y viii) evaluación de los resultados. Todas las recomendaciones fueron valoradas por el panel de expertos externos como adecuadas y necesarias. Conclusiones: el recorrido asistencial del paciente con hemofilia es complejo y depende de diversas variables. Además, requiere la implicación de distintos profesionales sanitarios que deben actuar de manera coordinada e integrada en todas las etapas de la vida del paciente, de manera adaptada a sus necesidades individuales. ... (AU)

Objective: Define consensus recommendations to improve care coordination between Hospital Pharmacy, Haematology and Nursing, inter- and intra-center, in the care of haemophilia patients.Method: Recommendations for the improvement of care coordination in the management of haemophilia patients were identified and assessed by a multidisciplinary panel of professionals with experience in this field (Hospital Pharmacy, Haematology and Nursing) and supported by scientific evidence. The identified recommendations were assessed by Rand/UCLA consensus methodology (Delphi-adapted) based on their appropriateness and, subsequently, on their necessity. In both cases, it was used ordinal Likert scale. Data were statistically analysed through different metrics. Results: Fifty-three recommendations for the improvement of care coordination between Hospital Pharmacy, Haematology and Nursing in the management of haemophilia patients were identified, grouped into eight areas of action: i) Haemophilia units, reference centers and multidisciplinary care; ii) Role of Haematology, Hospital Pharmacy and Nursing in the patient journey of haemophilia patients; iii) Telepharmacy and telemedicine; iv) Pharmacokinetic monitoring; v) Transition to adult patient regimen; vi) Patient health education; vii) Surgery, emergency room and hospital admission; and viii) Outcome evaluation. All recommendations were assessed as appropriate and necessary by the external expert panel. Conclusions: Haemophilia patient journey is complex and depends on different variables. It also requires the involvement of different healthcare professionals who must act in a coordinated and integrated manner at all stages of the patient's life, adapted to their individual needs. ... (AU)

[Translated article] Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

OBJECTIVE: Define consensus recommendations to improve care coordination between Hospital Pharmacy, Hematology and Nursing, inter- and intra-center, in the care of hemophilia patients. METHOD: Recommendations for the improvement of care coordination in the management of hemophilia patients were identified and assessed by a multidisciplinary panel of professionals with experience in this field (Hospital Pharmacy, Hematology and Nursing) and supported by scientific evidence. The identified recommendations were assessed by Rand/UCLA consensus methodology (Delphi-adapted) based on their appropriateness and, subsequently, on their necessity. In both cases, it was used ordinal Likert scale. Data were statistically analyzed through different metrics. RESULTS: Fifty-three recommendations for the improvement of care coordination between Hospital Pharmacy, Hematology and Nursing in the management of hemophilia patients were identified, grouped into eight areas of action: i) Hemophilia units, reference centers and multidisciplinary care; ii) Role of Hematology, Hospital Pharmacy and Nursing in the patient journey of hemophilia patients; iii) Telepharmacy and telemedicine; iv) Pharmacokinetic monitoring; v) Transition to adult patient regimen; vi) Patient health education; vii) Surgery, emergency room and hospital admission; and viii) Outcome evaluation. All recommendations were assessed as appropriate and necessary by the external expert panel. CONCLUSIONS: Hemophilia patient journey is complex and depends on different variables. It also requires the involvement of different healthcare professionals who must act in a coordinated and integrated manner at all stages of the patient's life, adapted to their individual needs. On this matter, the identified and agreed recommendations may improve continuity and quality of care, as they facilitate the integration and coordination of the professionals involved in the management of this pathology, especially Hospital Pharmacy, Hematology and Nursing.

Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia. / Consenso de recomendaciones para la mejora de la coordinación asistencial inter e intra-centros en el abordaje de la hemofilia.

OBJECTIVE: Define consensus recommendations to improve care coordination between Hospital Pharmacy, Haematology and Nursing, inter- and intra-center, in the care of haemophilia patients. METHOD: Recommendations for the improvement of care coordination in the management of haemophilia patients were identified and assessed by a multidisciplinary panel of professionals with experience in this field (Hospital Pharmacy, Haematology and Nursing) and supported by scientific evidence. The identified recommendations were assessed by Rand/UCLA consensus methodology (Delphi-adapted) based on their appropriateness and, subsequently, on their necessity. In both cases, it was used ordinal Likert scale. Data were statistically analysed through different metrics. RESULTS: Fifty-three recommendations for the improvement of care coordination between Hospital Pharmacy, Haematology and Nursing in the management of haemophilia patients were identified, grouped into eight areas of action: i) Haemophilia units, reference centers and multidisciplinary care; ii) Role of Haematology, Hospital Pharmacy and Nursing in the patient journey of haemophilia patients; iii) Telepharmacy and telemedicine; iv) Pharmacokinetic monitoring; v) Transition to adult patient regimen; vi) Patient health education; vii) Surgery, emergency room and hospital admission; and viii) Outcome evaluation. All recommendations were assessed as appropriate and necessary by the external expert panel. CONCLUSIONS: Haemophilia patient journey is complex and depends on different variables. It also requires the involvement of different healthcare professionals who must act in a coordinated and integrated manner at all stages of the patient's life, adapted to their individual needs. On this matter, the identified and agreed recommendations may improve continuity and quality of care, as they facilitate the integration and coordination of the professionals involved in the management of this pathology, especially Hospital Pharmacy, Haematology and Nursing.

Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?

OBJECTIVES: Abiraterone and enzalutamide are two oral novel androgen receptor axis-targeted agents approved for the treatment of castration-resistant prostate cancer (mCRPC). Despite the availability of multiple treatments, there is a need to improve the knowledge and management of these drugs in the real-world setting, especially in patient groups under-represented in clinical trials. Our aim was to review the outcome of patients with chemotherapy-naïve mCRPC treated with abiraterone or enzalutamide in routine clinical practice in order to identify factors that are predictive for response. METHODS: This observational retrospective study was performed in a Spanish tertiary hospital and included men with chemotherapy-naïve mCPRC who started treatment with abiraterone or enzalutamide between September 2012 and November 2018. The study end date was 30 October 2020. RESULTS: Ninety patients with mCRPC were included, 57 with abiraterone and 33 with enzalutamide. Median overall survival (OS) was 26.87 months (95% CI 19.68 to 34.05), with no difference found between the two treatment groups. Nine variables were related to increased OS in the univariate analysis: Eastern Cooperative Oncology Group (ECOG) performance status (0-1 vs 2), pain (need of opioids for cancer pain), visceral disease, ≥3 bone lesions, exclusively lymph node metastases, baseline prostate specific antigen (PSA) (<50 vs ≥50 ng/dL and <20 vs ≥20 ng/dL), haemoglobin (<12 vs ≥12 g/dL) and alkaline phosphatase (≤116 vs >116 IU/L). A PSA response >50% was observed in 65 patients (76.5%). In the multivariate analysis, ECOG performance status, pain, visceral disease and alkaline phosphatase provided independent prognostic information. Median OS by Kaplan-Meier analysis was significantly longer for patients with a PSA response (32.1 vs 17.9 months; HR 0.46, 95% CI 0.27 to 0.78; p=0.003). CONCLUSIONS: This study assessed the efficacy of abiraterone and enzalutamide in a real-world setting, including patients under-represented in pivotal studies. Some clinical factors were correlated with improved OS in chemotherapy-naïve men with mCPRC treated with these drugs.

Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies.

OBJECTIVE: To identify and promote initiatives aimed at improving the management by hospital pharmacists of patients with congenital  coagulopathies in the Spanish healthcare context. METHOD: A series of initiatives to improve the care of patients with congenital coagulopathies were identified, evaluated, and prioritized by a panel of hospital pharmacists. Prioritization was based on an assessment of each  initiative's impact and feasibility on a scale of 1 to 5. Once initiatives were  prioritized, those assigned the highest priority were grouped into three action  areas. RESULTS: Seven areas of activity were identified in which the role of hospital  pharmacists is key for the management of patients with congenital coagulopathies: coordination with the healthcare team; drug  evaluation and selection; dispensing; patient information and education;  pharmacotherapeutic follow-up; research and innovation in the field of  congenital coagulopathies; and capacity-building and training of hospital  pharmacists. Fifteen initiatives were considered a priority, with an average  impact score ≥ 3.8 and a feasibility score ≥ 3.2. A total of, 29.4% of the  prioritized initiatives corresponded to healthcare, 23.5% to patient information  and education, 11.8% to drug evaluation and selection, 11.8% to  phar macotherapeutic monitoring, 11.8% to cross-sectional initiatives, 5.9% to dispensing and 5.9% to research and innovation in the field of congenital coagulopathies: In contrast, initiatives related to capacity-building and training were not prioritized. CONCLUSIONS: Three main action areas were proposed based on the initiatives  identified as high priority for the management of patients with congenital  coagulopathies by a panel of 16 hospital pharmacists. Action areas revolved  around specific activities that hospital pharmacy departments can undertake to  contribute to improving the healthcare situation in Spain.

OBJETIVO: Identificar e impulsar iniciativas orientadas a la mejora del manejo  de los pacientes con coagulopatías congénitas por parte de farmacia hospitalaria en el contexto sanitario español.Método: Se identificaron, evaluaron y priorizaron, por parte de un panel de  farmacéuticos especialistas en farmacia hospitalaria, iniciativas para la mejora  de la atención a los pacientes con coagulopatías congénitas. La priorización se  realizó en base a la valoración de su impacto y factibilidad en una escala del 1  al 5. Una vez obtenida la priorización de las iniciativas, las de mayor  puntuación se agruparon en tres grandes líneas de actuación. RESULTADOS: Se identificaron siete áreas de actividad en las que el papel de  los farmacéuticos especialistas en farmacia hospitalaria resulta clave para el  manejo del paciente con coagulopatías congénitas: coordinación con el equipo  asistencial de pacientes con coagulopatías congénitas; evaluación y selección  de medicamentos; dispensación; información y formación al paciente;  seguimiento farmacoterapéutico; investigación e innovación en estas  patologías; formación y capacitación continuada del farmacéutico especialista  en farmacia hospitalaria. Se consideraron prioritarias 15 iniciativas por tener  una puntuación media de impacto ≥ 3,8 y factibilidad ≥ 3,2. Así, el 29,4% de  las iniciativas priorizadas pertenecen al ámbito asistencial, el 23,5% a  información y formación al paciente, el 11,8% a evaluación y selección de  medicamentos, el 11,8% al seguimiento farmacoterapéutico, el 11,8% a  iniciativas transversales, el 5,9% a dispensación y el 5,9% a investigación e  innovación en el campo de las coagulopatías congénitas, mientras que las  iniciativas referentes a la formación y capacitación a profesionales no  resultaron priorizadas. CONCLUSIONES: Se han propuesto tres grandes líneas de actuación basadas en  las iniciativas identificadas como altamente prioritarias por un panel de 16  expertos farmacéuticos especialistas en farmacia hospitalaria para el manejo  de pacientes con coagulopatías congénitas. Estas iniciativas se basan en  acciones concretas y pueden llevarse a cabo desde los servicios de farmacia  hospitalaria, por lo que se cree que podrán llegar a tener un impacto real en el  contexto sanitario español.

Iniciativas para la mejora del manejode los pacientes con coagulopatías congénitas por parte de farmacia hospitalaria / Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies

Objetivo: Identificar e impulsar iniciativas orientadas a la mejora delmanejo de los pacientes con coagulopatías congénitas por parte de farmaciahospitalaria en el contexto sanitario español.Método: Se identificaron, evaluaron y priorizaron, por parte de un panelde farmacéuticos especialistas en farmacia hospitalaria, iniciativas para lamejora de la atención a los pacientes con coagulopatías congénitas. Lapriorización se realizó en base a la valoración de su impacto y factibilidaden una escala del 1 al 5. Una vez obtenida la priorización de las iniciativas,las de mayor puntuación se agruparon en tres grandes líneas de actuación.Resultados: Se identificaron siete áreas de actividad en las que el papelde los farmacéuticos especialistas en farmacia hospitalaria resulta clavepara el manejo del paciente con coagulopatías congénitas: coordinacióncon el equipo asistencial de pacientes con coagulopatías congénitas;evaluación y selección de medicamentos; dispensación; información yformación al paciente; seguimiento farmacoterapéutico; investigacióne innovación en estas patologías; formación y capacitación continuadadel farmacéutico especialista en farmacia hospitalaria. Se consideraronprioritarias 15 iniciativas por tener una puntuación media de impacto≥ 3,8 y factibilidad ≥ 3,2. Así, el 29,4% de las iniciativas priorizadas pertenecen al ámbito asistencial, el 23,5% a información y formación alpaciente, el 11,8% a evaluación y selección de medicamentos, el 11,8%al seguimiento farmacoterapéutico, el 11,8% a iniciativas transversales, el5,9% a dispensación y el 5,9% a investigación e innovación en el campode las coagulopatías congénitas, mientras que las iniciativas referentesa la formación y capacitación a profesionales no resultaron priorizadas.

Objective: To identify and promote initiatives aimed at improving themanagement by hospital pharmacists of patients with congenital coagulopathiesin the Spanish healthcare context.Method: A series of initiatives to improve the care of patients with congenitalcoagulopathies were identified, evaluated, and prioritized by apanel of hospital pharmacists. Prioritization was based on an assessmentof each initiative’s impact and feasibility on a scale of 1 to 5. Once initiativeswere prioritized, those assigned the highest priority were groupedinto three action areas.Results: Seven areas of activity were identified in which the role ofhospital pharmacists is key for the management of patients with congenitalcoagulopathies: coordination with the healthcare team; drug evaluationand selection; dispensing; patient information and education; pharmacotherapeuticfollow-up; research and innovation in the field of congenitalcoagulopathies; and capacity-building and training of hospital pharmacists.Fifteen initiatives were considered a priority, with an average impactscore ≥ 3.8 and a feasibility score ≥ 3.2. A total of, 29.4% of the prioritizedinitiatives corresponded to healthcare, 23.5% to patient informationand education, 11.8% to drug evaluation and selection, 11.8% to pharmacotherapeutic monitoring, 11.8% to cross-sectional initiatives, 5.9% todispensing and 5.9% to research and innovation in the field of congenitalcoagulopathies: In contrast, initiatives related to capacity-building andtraining were not prioritized.Conclusions: Three main action areas were proposed based onthe initiatives identified as high priority for the management of patientswith congenital coagulopathies by a panel of 16 hospital pharmacists.Action areas revolved around specific activities that hospital pharmacydepartments can undertake to contribute to improving the healthcare situationin Spain.

Intervention by a clinical pharmacist carried out at discharge of elderly patients admitted to the internal medicine department: influence on readmissions and costs.

BACKGROUND: Patient education on pharmacological treatment could reduce readmissions. Our objective was to carry out a pharmacist intervention focused on providing information about high-risk medications to chronic patients and to analyse its influence on readmissions and costs. METHODS: A single-centre study with an intervention group and a retrospective control group was conducted. The intervention was carried out in all polymedicated patients ≥ 65 years who were admitted to internal medicine and signed the informed consent between June 2017 and February 2018. Patients discharged to nursing homes or long-term hospitals were excluded. The control group were all the patients who were admitted during the same months of 2014 who met the same inclusion criteria. The patients were classified according to the HOSPITAL score as having a low, intermediate, or high risk of potentially avoidable readmission. Outcome measures were 30-day readmission and cost data. To analyse the effect of the intervention on readmission, a logistic regression was performed. RESULTS: The study included 589 patients (286 intervention group; 303 control group). The readmission rate decreased from 20.13% to 16.43% in the intervention group [OR = 0.760 95% CI (0.495-1.166); p = 0.209)]. The incremental cost for the intervention to prevent one readmission was €3,091.19, and the net cost saving was €1,301.26. In the intermediate- and high-risk groups, readmissions were reduced 10.91% and 10.00%, and the net cost savings were €3,3143.15 and €3,248.71, respectively. CONCLUSIONS: The pharmacist intervention achieved savings in the number of readmissions, and the net cost savings were greater in patients with intermediate and high risks of potentially avoidable readmission according to the HOSPITAL score.

Safety and effectiveness of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal following a fixed-dose strategy.

OBJECTIVES: Early reversal of anticoagulation improves outcomes in major bleeding and emergency surgery. To reverse vitamin K antagonists (VKA), vitamin K in addition to prothrombin complex concentrate (PCC) is recommended. Dosing recommendations for VKA reversal provided by the manufacturer are 25-50 IU/kg depending on the baseline international normalised ratio (INR). Nevertheless, we recommend an initial fixed dose of 1000 IU, and additional 500 IU doses evaluated on a case-by-case basis. As there is a paucity of clinical data demonstrating the efficacy and safety of this strategy, we designed this study to assess the effectiveness and safety of a four-factor (4F)-PCC for VKA reversal following a fixed-dose strategy. METHODS: This was a retrospective study of adult patients who received 4F-PCC for VKA reversal. The primary outcome was INR correction. INR correction was achieved if the first INR draw after 4F-PCC was ≤1.5. Safety outcome was any confirmed thromboembolic event within 3 months after 4F-PCC. Secondary outcomes included activated partial thromboplastin time (aPTT) correction, as well as haemostatic effectiveness for bleeding patients. RESULTS: A total of 145 patients were included: 106 (73.1%) in the bleeding group and 39 (26.9%) in the emergency surgery group. The INR target was reached in 102 (70.3%) patients (p<0.0001). In one case, a thromboembolic complication was possibly related to 4F-PCC. The aPTT ratio target was reached in 113 (77.9%) patients (p<0.0001), and 79 of the 106 (74.5%) patients reversed for bleeding achieved haemostatic effectiveness. CONCLUSIONS: After 4F-PCC, the majority of patients achieved the target INR, meaning 4F-PCC is a useful modality for rapid INR reduction. The safety profile may be considered acceptable. Fixed-dose 4F-PCC was able to restore haemostasis rapidly while minimising the risk of adverse events and optimising available resources.

Plasma rico en plaquetas: actualización de los sistemas empleados para su obtención / Platelet-rich plasma: updating of extraction devices

Objetivo: Describir los dispositivos para la obtención de Plasma Rico en Plaquetas (PRP) mediante la revisión de los productos existentes en España, teniendo en consideración las aportaciones de la Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) y los grupos de trabajo de Productos Sanitarios (GPS), Farmacotecnia y Hemoderivados de la Sociedad Española de Farmacia Hospitalaria (SEFH). Método: Se realizaron tres búsquedas independientes sobre dispositivos de fraccionamiento de plasma. Se contactó con los proveedores y se estableció una reunión con cada uno de ellos. Se revisaron las características de cada dispositivo mediante una demostración del proceso de fraccionamiento virtual y se elaboró una tabla de comparación de kits. Los dispositivos se clasificaron como Técnica cerrada y Técnica abierta de acuerdo al informe del comité técnico de inspección de la AEMPS. Resultados: Se localizaron diez dispositivos: ACP®; Angel®, Cascade®, Endoret®, GPS®, Magellan®, Minos®, Ortho-pras®, Smart-prepr® y Tricell®, pudiendo conocer de forma detallada el funcionamiento en siete de ellos. Sin embargo, de Cascade®, Magellan® y Smart-prepr® no se consiguió información suficiente. Conclusión: La revisión permitió conocer los principales dispositivos de extracción de PRP disponibles con marcado CE y sus características diferenciales; sin embargo, para garantizar la cali dad del producto final es crucial poner atención en el propio proceso de extracción y administración del PRP. El Servicio de Farmacia debe implicarse en su selección por la estrecha relación que mantiene con la calidad del medicamento elaborado. El trabajo conjunto con la AEMPS permitirá definir de forma más específica el proceso correcto de elaboración (AU)

Propose: To describe PRP extraction devices, through a review of kits available in Spain, taking into account AEMPS and SEFH working groups (GPS, Farmacotecnia, Hemoderivados groups) contributions. Methods: Three independent searches about PRP extraction devices were carried out. Device suppliers were contacted and an individually meeting was called with each one. Characteristics of each device was reviewed by virtual demonstration. A kits comparison chart was made with all the information acquired. Kits were classified as Closed-Technique and Opened-Technique in accordance with the AEMPS technical committee report. Results: Ten devices were found: ACP®; Angel®, Cascade®, Endoret®, GPS®, Magellan®, Minos®, Ortho-pras®, Smart-prepr® and Tricell®. However, we could found out the mechanism in detail of seven of them. Information about Cascade®, Magellan® and Smart-prepr® kits was not enough. Conclusion: The review provided the main PRP extraction devices available with CE marking and its distinguishing characteristics, however, it is crucial to pay attention to PRP extraction procedure and administration, to guarantee the final product quality. Pharmacy Department must get involved in the device selections due to the close link with the manufactured drug quality. Working together with the AEMPS will contribute to defining extraction procedure specifically (AU)

[Platelet-rich plasma: updating of extraction devices]. / Plasma rico en plaquetas: actualización de los sistemas empleados para su obtención.

UNLABELLED: Propose: To describe PRP extraction devices, through a review of kits available in Spain, taking into account AEMPS and SEFH working groups (GPS, Farmacotecnia, Hemoderivados groups) contributions. METHODS: Three independent searches about PRP extraction devices were carried out. Device suppliers were contacted and an individually meeting was called with each one. Characteristics of each device was reviewed by virtual demonstration. A kits comparison chart was made with all the information acquired. Kits were classified as Closed-Technique and Opened- Technique in accordance with the AEMPS technical committee report. RESULTS: Ten devices were found: ACP®; Angel®, Cascade®, Endoret ®, GPS®, Magellan®, Minos®, Ortho-pras®, Smart-prepr® and Tricell®. However, we could found out the mechanism in detail of seven of them. Information about Cascade®, Magellan ® and Smart-prepr® kits was not enough. CONCLUSION: The review provided the main PRP extraction devices available with CE marking and its distinguishing characteristics, however, it is crucial to pay attention to PRP extraction procedure and administration, to guarantee the final product quality. Pharmacy Department must get involved in the device selections due to the close link with the manufactured drug quality. Working together with the AEMPS will contribute to defining extraction procedure specifically.

Objetivo: Describir los dispositivos para la obtención de Plasma Rico en Plaquetas (PRP) mediante la revisión de los productos existentes en España, teniendo en consideración las aportaciones de la Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) y los grupos de trabajo de Productos Sanitarios (GPS), Farmacotecnia y Hemoderivados de la Sociedad Española de Farmacia Hospitalaria (SEFH). Método: Se realizaron tres búsquedas independientes sobre dispositivos de fraccionamiento de plasma. Se contactó con los proveedores y se estableció una reunión con cada uno de ellos. Se revisaron las características de cada dispositivo mediante una demostración del proceso de fraccionamiento virtual y se elaboró una tabla de comparación de kits. Los dispositivos se clasificaron como Técnica cerrada y Técnica abierta de acuerdo al informe del comité técnico de inspección de la AEMPS. Resultados: Se localizaron diez dispositivos: ACP®; Angel®, Cascade®, Endoret®, GPS®, Magellan®, Minos®, Ortho-pras®, Smart-prepr® y Tricell®, pudiendo conocer de forma detallada el funcionamiento en siete de ellos. Sin embargo, de Cascade ®, Magellan® y Smart-prepr® no se consiguió información suficiente. Conclusión: La revisión permitió conocer los principales dispositivos de extracción de PRP disponibles con marcado CE y sus características diferenciales; sin embargo, para garantizar la calidad del producto final es crucial poner atención en el propio proceso de extracción y administración del PRP. El Servicio de Farmacia debe implicarse en su selección por la estrecha relación que mantiene con la calidad del medicamento elaborado. El trabajo conjunto con la AEMPS permitirá definir de forma más específica el proceso correcto de elaboración.